However, a few clinical trials showed that the anti-diabetic (e.g. rosiglitazone) [41], anti-hypertensive (e.g. amlodipine) [31] and anti-dyslipidemic (e.g. pitavastatin) [42] drugs were able to reduce circulating resistin levels and may contribute to improving insulin action in patients with T2DM and MS. This evidence concerns the gene RETN and myeloid sarcoma.